Access Criteria assessment tool
This guide is intended to help clinicians assess whether their patient is eligible for funded COVID-19 antiviral treatments under section 4 of the access criteria.
* As per Ministry of Health criteria(external link) of ‘severe immunocompromise’ for third primary dose
- Patients must also meet criteria 1, 2, 3 and 5 to be eligible for funded antiviral COVID-19 treatments.
- You may get an error message saying you have unsaved changes when you leave or refresh this page. You can ignore this message.